Literature DB >> 17868015

Pharmacological treatment of pain in multiple sclerosis.

Claudio Solaro1, Paolo Tanganelli, Michele Messmer Uccelli.   

Abstract

Pain is a common symptom in multiple sclerosis (MS) and was recently estimated to be experienced by up to 75% of patients. Nociceptive and neuropathic pain in MS may be present concurrently and at different stages of the disease and may be associated with other symptoms. Evidence for treating pain in MS is limited. Many clinical features of pain are often unrecognized by clinicians and are difficult for patients to describe. Treatment is often based on anecdotal reports and clinical experience. We present a review of treatment options for pain in MS that should serve to update current knowledge, highlight shortcomings in clinical research and provide indications towards achieving evidence-based treatment of pain in MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868015     DOI: 10.1586/14737175.7.9.1165

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  5 in total

Review 1.  Multiple sclerosis-related central pain disorders.

Authors:  Turo J Nurmikko; Sameer Gupta; Kate Maclver
Journal:  Curr Pain Headache Rep       Date:  2010-06

Review 2.  Painful and involuntary multiple sclerosis.

Authors:  Francesca Bagnato; Diego Centonze; Simonetta Galgani; Maria Grazia Grasso; Shalom Haggiag; Stefano Strano
Journal:  Expert Opin Pharmacother       Date:  2011-02-17       Impact factor: 3.889

3.  The symptomatic management of multiple sclerosis.

Authors:  Randall T Schapiro
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

4.  No Immediate Effects of Transcranial Direct Current Stimulation at Various Intensities on Cerebral Blood Flow in People with Multiple Sclerosis.

Authors:  Craig D Workman; Laura L Boles Ponto; John Kamholz; Thorsten Rudroff
Journal:  Brain Sci       Date:  2020-02-04

5.  Cannabis for Neuropathic Pain in Multiple Sclerosis-High Expectations, Poor Data.

Authors:  Thorsten Rudroff
Journal:  Front Pharmacol       Date:  2019-10-22       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.